Epilepsy

Capsida’s CAP-002 gene therapy, currently advancing through IND-enabling studies, aims to address the unmet needs of patients with STXBP1-related developmental and epileptic encephalopathy by stably supplementing STXBP1 protein.

Italo Linfante, MD, director of interventional neuroradiology at Baptist Health Miami Neuroscience Institute, discussed the importance of brain aneurysms in the context of neurology.

SEEG has transformed the surgical investigation of refractory epilepsy, enabling clinicians to map complex seizure networks with precision, leading to more targeted treatment options for patients.

Neurology News Network. for the week ending November 9, 2024. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 8, 2024.

M. Scott Perry, MD, an expert in epileptic disorders and board president of PERC, provided insights on the group's mission and goals, its structure and membership, and its 60+ ongoing research projects.

Rapport Therapeutics’ is actively recruiting patients for its phase 2a trial investigating its lead therapy candidate RAP-219 among patients with focal epilepsy, with topline data anticipated in mid-2025.

Diego Torres-Russotto, MD, chair of neurology at Baptist Health Miami Neuroscience Institute, discussed the Miami Neuroscience Symposium’s focus on addressing the community’s neurological needs, balancing content delivery and fostering multidisciplinary collaboration.

Michael McDermott, MD, chief medical executive at Baptist Health Miami Neuroscience Institute, gave greater insights on the institute’s annual symposium, which offers attendees updates in cutting-edge imaging, surgical techniques, and neurocognitive research.

Michael McDermott, MD, chief medical executive at Baptist Health Miami Neuroscience Institute, gave greater insights on the institute’s annual symposium, which offers attendees updates in cutting-edge imaging, surgical techniques, and neurocognitive research.

The data scientist at Roche and mother of a child living with Lennox-Gastaut syndrome, provided insight on areas of the disease that need greater recognition, as well as an overview of how the disease is currently treated. [WATCH TIME: 4 minutes]

Bruce Leuchter, MD, president and chief executive officer at Neurvati Neurosciences, provided clinical insight on the newly initiated Astroscape trial of radiprodil for the treatment of tuberous sclerosis complex and focal cortical dysplasia type II.

Ahead of International LGS Awareness Day, Melanie Huntley, PhD, a data scientist for Roche and mother of child with Lennox-Gastaut syndrome, shed light on the realities of living with LGS, emphasizing the need for greater awareness of the condition’s impact.

The professor of neurology at NYU Grossman School of Medicine discussed the results of a phase 2b study on XEN1101, an investigational drug in development for focal epilepsy. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The professor of neurology at NYU Grossman School of Medicine provided clinical insight on the uniqueness of investigational XEN1101 and the idea behind potassium channel inhibitors to treat epilepsy. [WATCH TIME: 3 minutes]

Scott Perry, MD, discusses how effective management of Dravet syndrome requires a multidisciplinary approach, emphasizing the critical importance of early diagnosis and aggressive treatment aimed at achieving seizure freedom, which can significantly improve long-term outcomes and quality of life for patients.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Lennox-Gastaut syndrome.

Scott Perry, MD, discusses how caregivers of patients with Dravet syndrome face significant challenges and emphasizes the importance of health care providers navigating sensitive conversations with empathy, clear communication, and comprehensive support to address caregivers’ concerns and needs.

Scott Perry, MD, discusses how treatment challenges in Dravet syndrome necessitate careful monitoring by health care providers, who must consider factors such as individual patient response, adverse effect profiles, drug interactions, and the potential need for escalation therapy, to optimize seizure control and overall patient outcomes.

Here's some of what is coming soon to NeurologyLive® this week.

The panelist discusses how the goal of Dravet syndrome treatment is to reduce seizure frequency and severity, typically starting with initial treatments like valproate and clobazam and potentially escalating to combination therapies including options such as cannabidiol, with the overall aim of improving patients’ quality of life and developmental outcomes

Scott Perry, MD, discusses how pediatric patients with Dravet syndrome often experience various comorbidities alongside seizures, including developmental delays, behavioral issues, and sleep disturbances, which significantly impact quality of life, especially when diagnosis is delayed, necessitating comprehensive management strategies.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 4, 2024.

Scott Perry, MD, discusses how Dravet syndrome is diagnosed through a combination of clinical observation, genetic testing, and phenotypic evaluation, emphasizing the challenges and importance of early diagnosis to improve patient outcomes.

Scott Perry, MD, discusses how Dravet syndrome is a rare genetic epilepsy characterized by frequent, prolonged seizures beginning in infancy, often accompanied by developmental delays and other health issues that persist and evolve as patients age.

Here's some of what is coming soon to NeurologyLive® this week.

Innovative neurosurgical advances in imaging/mapping, robotic assistance, and extended reality enable surgeons to more precisely and effectively treat neurological conditions such as brain tumor, epilepsy, Parkinson Disease, and stroke, giving patients new hope and a chance for more successful outcomes.